Comparative pharmacophore development for inhibitors of human and rat 5-α-reductase

Journal of Molecular Graphics and Modelling

Volumn 22, Issue 1, 2003, Pages 83-92

  Faragalla, Jane ^a   Bremner, John ^a   Brown, David ^b   Griffith, Renate ^c   Heaton, Andrew ^b  

^a UNIVERSITY OF WOLLONGONG   (Australia)

^b Novogen Ltd   (Australia)

^c UNIVERSITY OF NEWCASTLE   (Australia)

Author keywords

5 reductase; Inhibitors; Pharmacophore; Structure activity relationships; Training set randomization; Variable weight pharmacophore

Indexed keywords

CRYSTAL STRUCTURE; DISEASES; DRUG THERAPY;

PHARMACOPHORE DEVELOPMENT;

ENZYME INHIBITION;

STEROID 5ALPHA REDUCTASE INHIBITOR;

ARTICLE; DRUG DESIGN; ENZYME INHIBITION; HUMAN; NONHUMAN; PHARMACOPHORE; PRIORITY JOURNAL; RAT;

EID: 0038205810     PISSN: 10933263     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1093-3263(03)00138-4     Document Type: Article

References (25)

1. Jin Y., Penning T.M. Steroid 5-α-reductases and 3α-hydroxysteroid dehydrogenases: key enzymes in androgen metabolism. Best Pract. Res. Clin. Endocrinol. Metabol. 15:2001;79-94.
2. Machetti F., Guarna A. Novel inhibitors of 5-α-reductase. Expert Opin. Therap. Patents. 12:2002;201-215.
3. Cilotti A., Danza G., Serio M. Clinical application of 5-α-reductase inhibitors. J. Endocrinol. Invest. 24:2001;199-203.
4. Papatsoris A.G., Papavassiliou A.G. Prostate cancer: horizons in the development of novel anti-cancer strategies. Curr. Med. Chem. 1:2001;47-70.
5. Thigpen A.E., Silver R.I., Guileyardo J.M., Casey M.L., Mc Connell J.D., Russell D.W. Tissue distribution and ontogeny of steroid 5-alpha-reductase isozyme expression. J. Clin. Invest. 92:1993;903-910.
6. Russell D.W., Wilson J.D., Jean D. Steroid 5-alpha reductase: two genes/two enzymes. Annu. Rev. Biochem. 63:1994;25-61.
7. Liang T., Cascieri M.A., Cheung A.H., Reynolds G.F., Rasmusson G.H. Species differences in prostatic steroid 5-α-reductase of rat, dog, and human. Endocrinology. 117:1985;571-579.
8. Kurup A., Garg R., Hansch C. Comparative QSAR analysis of 5-α-reductase inhibitors. Chem. Rev. 100:2000;909-924.
9. Abell A.D., Prince M.J., Mc Nulty A.M., Neubauer B.L. Simple Bi and tricyclic inhibitors of human steroid 5-α-reductase. Bioorg. Med. Chem. Lett. 10:2000;1909-1911.
10. Guarna A., Machetti F., Occhiato E.G., Scarpi D., Comerci A., Danza G., Mancina R., Serio M., Hardy K. Benz[c]quinolizin-3-ones: a novel class of potent and selective non-steroidal inhibitors of human steroid 5-α-reductase1. J. Med. Chem. 43:2000;3718-3735.
11. Picard F., Schulz T., Hartmann R.W. 5-phenyl substituted 1-methyl-2-pyridones and 4′-substituted biphenyl-4-carboxylic. Acids synthesis and evaluation as inhibitors of steroid-5-α-reductase type 1 and 2. Bioorg. Med. Chem. Lett. 10:2002;437-448.
12. Takami H., Koshimura H., Kishibayashi N., Ishii A., Nonaka H., Aoyama S., Kase H., Kumazawa T. Indole derivatives as a new class of steroid 5 α-reducatse inhibitors. J. Med. Chem. 39:1996;5047-5052.
13. Sawada K., Hirai H., Golden P., Okada S., Sawada Y., Hashimoto M., Tanaka H. (1-Benzylindole-3-yl)alkanoic acids; novel non-steroidal inhibitors of steroidal 5-α-reductase (I). Chem. Pharm. Bull. 46:1998;1683-1687.
14. Sawada K., Golden P., Okada S., Kayakiri N., Sawada Y., Hashimoto M., Tanaka H. 4-(1-Benzoyl(indole-3-yl)butyric acids and FK 143: novel non-steroidal inhibitors of steroid 5-α-reductase (II). Chem. Pharm. Bull. 47:1999;481-491.
15. Igarashi S., Inami H., Hara H., Fujii M., Koutoku H., Oritani H., Mase T. A novel class of inhibitors for human steroid 5-α-reductase: synthesis and biological evaluation of indole derivatives (II). Chem. Pharm. Bull. 48:2000;382-388.
16. Chen G.S., Chang C-S., Kan W.M., Chang C.-L., Wang K.C., Chern J.-W. Novel lead generation through hypothetical pharmacophore three-dimensional database searching: discovery of isoflavonoids as non-steroidal inhibitors of rat 5-α-reductase. J. Med Chem. 44:2001;3759-3763.
17. Sudduth S.L., Koronkowski M.J. Finasteride: the first 5-alpha-reductase inhibitor. Pharmacotherapy. 13:1993;309-325.
18. H. Li, J. Sutter, R. Hoffman, Hypogen: an automated system for generating 3D predictive pharmacophore models in pharmacophore perception, development, and use, in: O.F. Guner (Ed.), Drug Design, vol. 175, International University Line, La Jolla, CA, 2000 (Chapter 10).
19. Span P.N., Smals A.G.H., Sweep C.G.J., Benraad T.J. Rat steroid 5-α-reductase kinetic characteristics: extreme pH-dependancy of the type II isozyme in prostate and epididymis homogenates. J. Steroid Biochem. Metabol. 53:1995;185-192.
20. Smellie A., Teig S.L., Towbin P. Poling: promoting conformational variation. J. Comp. Chem. 16:1995;171-187.
21. Smellie A., Kahn S.D., Teig S.L. Analysis of conformational coverage. 1. Validation and estimation of coverage. J. Chem. Inf. Comp. Sci. 35:1995;285-294.
22. Smellie A., Kahn S.D., Teig S.L. Analysis of conformational coverage. 2. Applications of conformational models. J. Chem. Inf. Comp. Sci. 35:1995;295-304.
23. CATALYST® Tutorials Release 4.5, Molecular Simulations Inc., San Diego, 1999, pp. 256-262.
24. http://www.accelrys.com/catalyst/cathypo.html.
25. H.J. Bohm, S. Fischer, De novo ligand design, in: P.V.R. Schleyer, N.L. Allinger, T. Clark, J Gasteiger, P.A. Kollman, H.F. Schaefer III, P.R. Schreiner (Eds.), Encycylopedia of Computational Chemistry, Wiley, Chichester, UK, 1998, pp. 657-663.